drugset / Trial / NCT01097070
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals.
Timeline
- Start
- 2008-11
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevirimat | Small molecule | 200 mg | — |
| Subject | Bevirimat | Small molecule | 300 mg | — |
| Subject | Bevirimat | Small molecule | 400 mg | — |